WO2009061131A3 - Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same - Google Patents

Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same Download PDF

Info

Publication number
WO2009061131A3
WO2009061131A3 PCT/KR2008/006527 KR2008006527W WO2009061131A3 WO 2009061131 A3 WO2009061131 A3 WO 2009061131A3 KR 2008006527 W KR2008006527 W KR 2008006527W WO 2009061131 A3 WO2009061131 A3 WO 2009061131A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutically acceptable
pharmaceutical composition
acceptable salts
tricyclic derivatives
Prior art date
Application number
PCT/KR2008/006527
Other languages
French (fr)
Other versions
WO2009061131A2 (en
Inventor
Jong-Hee Choi
Myung-Hwa Kim
Seung Hyun Kim
Chun-Ho Park
Bo-Young Joe
Kwangwoo Chun
Byung-Kyu Oh
Dongkyu Ryu
Ran Won
Ji-Seon Park
Kwang Hee Kim
Han-Chang Lee
Ji Soo Choi
Original Assignee
Je Il Pharmaceutical Co Ltd
Jong-Hee Choi
Myung-Hwa Kim
Seung Hyun Kim
Chun-Ho Park
Bo-Young Joe
Kwangwoo Chun
Byung-Kyu Oh
Dongkyu Ryu
Ran Won
Ji-Seon Park
Kwang Hee Kim
Han-Chang Lee
Ji Soo Choi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Je Il Pharmaceutical Co Ltd, Jong-Hee Choi, Myung-Hwa Kim, Seung Hyun Kim, Chun-Ho Park, Bo-Young Joe, Kwangwoo Chun, Byung-Kyu Oh, Dongkyu Ryu, Ran Won, Ji-Seon Park, Kwang Hee Kim, Han-Chang Lee, Ji Soo Choi filed Critical Je Il Pharmaceutical Co Ltd
Publication of WO2009061131A2 publication Critical patent/WO2009061131A2/en
Publication of WO2009061131A3 publication Critical patent/WO2009061131A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to novel tricyclic derivatives having an excellent inhibitory activity on poly (ADP-ribose) polymerase, or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The tricyclic derivatives of the present invention inhibit the activity of poly (ADP-ribose) polymerase, thereby being used for the prevention or treatment of diseases that are caused by excessive activation of PARP, in particular, neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathic pain, inflammatory diseases, osteoporosis, and cancer.
PCT/KR2008/006527 2007-11-06 2008-11-06 Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same WO2009061131A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0112573 2007-11-06
KR1020070112573A KR101179753B1 (en) 2007-11-06 2007-11-06 Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
WO2009061131A2 WO2009061131A2 (en) 2009-05-14
WO2009061131A3 true WO2009061131A3 (en) 2009-06-25

Family

ID=40626341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/006527 WO2009061131A2 (en) 2007-11-06 2008-11-06 Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same

Country Status (2)

Country Link
KR (1) KR101179753B1 (en)
WO (1) WO2009061131A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2364983E (en) * 2008-11-11 2014-01-07 Jeil Pharmaceutical Co Ltd Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9163003B2 (en) 2011-07-13 2015-10-20 Novartis Ag 4-piperidinyl compounds for use as tankyrase inhibitors
CN103814032A (en) * 2011-07-13 2014-05-21 诺华股份有限公司 4-oxo-3,5,7,8-tetrahydro-4h-pyrano{4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
WO2013012723A1 (en) 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
EP3312177B1 (en) * 2015-06-09 2021-04-14 Onconic Therapeutics Inc. Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
CN107602446B (en) * 2016-07-12 2020-04-07 中国科学院上海药物研究所 1, 4-disubstituted-1, 2,3, 6-tetrahydropyridine compound, preparation method thereof, pharmaceutical composition and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009386A1 (en) * 1978-09-22 1980-04-02 Pfizer Inc. 2,10-Disubstituted dibenzo(b,d)pyrans and benzo(c)quinolines and pharmaceutical compositions thereof
WO2002028183A1 (en) * 2000-09-19 2002-04-11 Syngenta Limited Fungicides
WO2003080581A1 (en) * 2002-03-26 2003-10-02 Fujisawa Pharmaceutical Co., Ltd. Phenanthridinones as parp inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009386A1 (en) * 1978-09-22 1980-04-02 Pfizer Inc. 2,10-Disubstituted dibenzo(b,d)pyrans and benzo(c)quinolines and pharmaceutical compositions thereof
WO2002028183A1 (en) * 2000-09-19 2002-04-11 Syngenta Limited Fungicides
WO2003080581A1 (en) * 2002-03-26 2003-10-02 Fujisawa Pharmaceutical Co., Ltd. Phenanthridinones as parp inhibitors

Also Published As

Publication number Publication date
KR20090046431A (en) 2009-05-11
WO2009061131A2 (en) 2009-05-14
KR101179753B1 (en) 2012-09-04

Similar Documents

Publication Publication Date Title
WO2010056038A2 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
WO2009061131A3 (en) Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
WO2008061720A3 (en) Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2012019426A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008070016A3 (en) Inhibitors of akt activity
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007022225A3 (en) Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2012019430A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
WO2007149907A3 (en) Pyrazoloquinazolinones as parp inhibitors
WO2006091395A3 (en) Inhibitors of akt activity
WO2009043353A3 (en) Micromirs
WO2012019427A8 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2007131016A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2008070268A3 (en) Pharmaceutical compositions
WO2006110638A3 (en) Inhibitors of akt activity
WO2009082134A3 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
WO2007075923A3 (en) Treatment of synucleinopathies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08846727

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08846727

Country of ref document: EP

Kind code of ref document: A2